TVTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Travere Therapeutics Inc (TVTX) does not present a compelling buy opportunity for a beginner, long-term investor at this time. While there are some positive catalysts such as analyst upgrades and technical bullish indicators, the insider selling trend, lack of significant recent congress trading data, and mixed financial performance suggest a cautious approach. The investor's impatience and preference for long-term stability do not align with the current mixed signals for this stock.
The technical indicators show a bullish trend with MACD positively expanding, RSI in the neutral zone, and moving averages in a bullish alignment (SMA_5 > SMA_20 > SMA_200). However, the current price is slightly below the key pivot level of 30.982, indicating limited immediate upside potential.
Analysts have raised price targets recently, with Piper Sandler increasing to $38 and BofA increasing to $44, reflecting optimism about the stock.
FDA's consistent messaging on proteinuria reduction as an approvable endpoint for FSGS is a positive signal for Travere Therapeutics' drug pipeline.
The company is actively attracting talent with inducement RSUs, which could enhance its workforce and operations.
Insider selling has increased by 125.53% over the last month, which could indicate a lack of confidence from within the company.
Net income and EPS have significantly declined YoY in Q3 2025, showing financial instability.
Lack of significant hedge fund activity and no recent congress trading data suggest limited institutional or political confidence in the stock.
In Q3 2025, revenue increased significantly by 162.11% YoY to $164.86M, and gross margin improved slightly to 99.04%. However, net income dropped by -146.90% YoY to $25.71M, and EPS fell by -135.71% YoY to 0.25, indicating profitability challenges.
Analysts are cautiously optimistic, with Piper Sandler maintaining a Neutral rating and BofA keeping a Buy rating. Price targets have been raised, but upcoming Q4 earnings may not have a significant impact due to pre-announcements.
